Anlon HealthcareNSE:AHCL -3.47%28 PS Ratio is 5.30 as of Jul. 07, 2026, which is 2% above its 10-year median of 5.18. GuruFocus rates NSE:AHCL with a GF Score™ of 28/100. The stock has 5 warning signs investors should review. Among 951 Drug Manufacturers companies, Anlon Healthcare ranks worse than 74.66% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Anlon Healthcare's share price is ₹15.32.
Anlon Healthcare's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ₹2.89. Hence, Anlon Healthcare's PS Ratio for today is 5.30.
Good Sign:
Anlon Healthcare Ltd stock PS Ratio (=4.31) is close to 1-year low of 3.91.
The historical rank and industry rank for Anlon Healthcare's PS Ratio or its related term are showing as below:
NSE:AHCL'
s PS Ratio Range Over the Past 10 Years
Min: 3.91 Med: 5.18 Max: 8.11
Current: 5.3
During the past 5 years, Anlon Healthcare's highest PS Ratio was 8.11. The lowest was 3.91. And the median was 5.18.
NSE:AHCL's PS Ratio is ranked worse than 74.66% of 951
companies
in the Drug Manufacturers industry
Industry Median: 2.28
vs NSE:AHCL: 5.30
During the past 5 years, Anlon Healthcare's highest 3-Year average Revenue per Share Growth Rate was 28.20% per year. The lowest was 20.20% per year. And the median was 24.20% per year.
Back to Basics: PS Ratio
Anlon Healthcare (NSE:AHCL) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Anlon Healthcare PS Ratio Related Terms
Anlon Healthcare PS Ratio Historical Data
* Premium members only.
The historical data trend for Anlon Healthcare's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Anlon Healthcare's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anlon Healthcare PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Anlon Healthcare's PS Ratio distribution charts can be found below:
* The bar in red indicates where Anlon Healthcare's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Anlon Healthcare's Share Price of today is ₹15.32. Anlon Healthcare's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹2.89.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Anlon Healthcare (NSE:AHCL) has a PS Ratio of 5.30 as of Jul. 07, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Anlon Healthcare and its competitors. This is near median its historical median of 5.18. Over the past decade, Anlon Healthcare's PS Ratio has ranged from 3.91 to 8.11. According to the industry distribution chart, Anlon Healthcare ranks #710 out of 951 companies in the Drug Manufacturers industry, placing it in the top 74.7%.
Is Anlon Healthcare's PS Ratio too high?
Anlon Healthcare's current PS Ratio of 5.30 is near median its 10-year median of 5.18. Over the past 10 years, this metric has ranged from a low of 3.91 to a high of 8.11. The Drug Manufacturers industry median PS Ratio is 2.28. Anlon Healthcare's value of 5.30 is 132.5% above this industry median. Based on the distribution chart, Anlon Healthcare ranks #710 out of 951 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Anlon Healthcare has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Anlon Healthcare's PS Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Anlon Healthcare ranks #710 out of 951 companies for PS Ratio. This places Anlon Healthcare in the lower half of its industry. The industry median PS Ratio is 2.28. Anlon Healthcare's value of 5.30 is 132.5% above this benchmark. Historically, Anlon Healthcare's own PS Ratio has ranged from 3.91 to 8.11 over the past decade. While the company's 10-year median is 5.18 vs. the industry median of 2.28, Anlon Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.28, based on 951 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anlon Healthcare's current PS Ratio of 5.30 is 132.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Anlon Healthcare and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anlon Healthcare's current PS Ratio is 5.30, which is near median its own 10-year median of 5.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anlon Healthcare stock overvalued right now?
Anlon Healthcare (NSE:AHCL) has a current PS Ratio of 5.30. The current PS Ratio is 5.30, which is near median its 10-year median of 5.18 and 132.5% above the Drug Manufacturers industry median of 2.28. Anlon Healthcare's overall GF Score™ is 28/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Anlon Healthcare (NSE:AHCL), the current PS Ratio is 5.30 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anlon Healthcare Ltd is a chemical manufacturing company engaged in manufacturing of; (i) high purity advance pharmaceutical intermediates which serves as raw material/ key starting material in the manufacturing of active pharmaceutical ingredients; and (ii) active pharmaceutical ingredients which serves as a raw material for pharmaceutical formulations in preparation of various type of Finished Dosage Formula such as tablet, capsules, ointment, syrup etc, ingredients in nutraceuticals formulations, personal care products and animal health products. Its products spans across the family of pharmaceutical intermediates, active pharmaceutical ingredients, nutraceutical APIs and ingredients for personal care and veterinary API.
28GF Score
Get the complete analysis for NSE:AHCL
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:AHCL has been successfully added to your 
